The invention provides a method for inducing human primordial germ cell-like (PGC-like) cells from human pluripotent stem cells, with high efficiency and high reproducibility, and a cell surface marker for identifying human PGC-like cells. In particular, the invention provides a method for producing a human PGC-like cell from a human pluripotent stem cell, includes a step of producing a mesoderm-like cell by culturing a human pluripotent stem cell in a culture medium comprising activin A and a GSK3 inhibitor, and a step of culturing the mesoderm-like cell in a culture medium containing BMP. The invention also provides a method for producing an isolated human PGC-like cell, which includes the aforementioned two steps and the additional step of selecting a cell positive to at least one cell surface marker selected from the group consisting of PECAM (CD31), INTEGRINa6 (CD49f), INTEGRIN3 (CD61), KIT (CD117), EpCAM, PODOPLANIN and TRA1-81.

A means for detecting in vitro the presence or absence of antibody mediated rejection (ABMR) in patients after organ transplantation in a simple manner at an early stage not through biopsy of organs is provided. A method for detecting in vitro the presence or absence of antibody mediated rejection (hereinafter referred to as ABMR) in patients after organ transplantation, comprising culturing peripheral blood sample from the patients in the presence of humoral factors from activated T cells and/or inflammatory cytokines, and detecting IgM-type DSA in the culture supernatant, wherein the detection of IgM-type DSA can be an index of early diagnosis of ABMR, and a kit used for said method.

Provided are a method of preparing a stem cell-derived epidermal progenitor cell conditioned medium, the method including: differentiating stem cells to stem cell-derived epidermal progenitor cells by culturing the stem cells in a differentiation medium containing ascorbic acid and hydrocortisone; producing a culture of stem cell-derived epidermal progenitor cells by culturing the differentiated stem cell-derived epidermal progenitor cells in a medium; and recovering the stem cell-derived epidermal progenitor cell conditioned medium from the culture of the stem cell-derived epidermal progenitor cells, a stem cell-derived epidermal progenitor cell conditioned medium prepared by the method, and a method of producing a protein from stem cell-derived epidermal progenitor cells, the method including the method of preparing the stem cell-derived epidermal progenitor cell conditioned medium.

A method for expanding a population of T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-) under conditions in which the production of effector T-cells having therapeutic activity against malignant disease is favored. The use of TGF- in the production of effector cells in particular V9V2 T-cells is also described and claimed.

This invention relates to a novel approach for the generation of human induced neural border stem cells (iNBSCs) by the direct conversion of somatic cells (peripheral blood, skin biopsies) and to novel uses of such cells, including the differentiation of these stem cells into cell types of the CNS and the neural crest lineages, and the uses of such cells.

A method for expanding a population of T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-) under conditions in which the production of effector T-cells having therapeutic activity against malignant disease is favored. The use of TGF- in the production of effector cells in particular V9V2 T-cells is also described and claimed.

The present invention provides a novel method for manufacturing a protein, particularly where said protein is to be coupled with another molecule. The invention further provides a method for industrial scale protein manufacturing to obtain proteins, e.g., for therapeutic purposes.

The invention provides cellular compositions that contain CD34.sup.+ cells derived from bone marrow of a decease donor and CD3.sup.+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.

The present invention relates to a method of preparing hematopoietic cell graft or enriching a population of cells for hematopoietic stem cells that are capable of long-term multilineage engraftment and self-renewal. It also relates to hematopoietic grafts comprising said hematopoietic stem cells as well as their uses in therapy.

The present disclosure provides methods for producing bioengineered tissue along with an apparatus and other relevant compositions employed in generation thereof.